XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Ordinary Shares
Additional paid-in- capital
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 16,499 $ (3,678) $ 12,821
Balance (in Shares) at Dec. 31, 2022 1,180,167      
Net loss for the period (1,828) (1,828) [1]
Issuance of ordinary shares to SciSparc Ltd. (see note 3b.) 288 288
Issuance of ordinary shares to SciSparc Ltd. (see note 3b.) (in Shares) 35,345      
Balance at Jun. 30, 2023 16,787 (5,506) 11,281
Balance (in Shares) at Jun. 30, 2023 1,215,512      
Balance at Dec. 31, 2023 16,787 (8,276) $ 8,511
Balance (in Shares) at Dec. 31, 2023 1,215,512     1,215,512
Net loss for the period (3,875) $ (3,875) [1]
Issuance of ordinary shares pre-funded warrants and warrants, net (note 4a.) 2,557 2,557
Issuance of ordinary shares pre-funded warrants and warrants, net (note 4a.) (in Shares) 1,884,461      
Exercise of Series B Warrants (note 4a.)
Exercise of Series B Warrants (note 4a.) (in Shares) 5,257,127      
Exercise of Pre-Funded Warrants (note 4a.)
Exercise of Pre-Funded Warrants (note 4a.) (in Shares) 820,000      
Balance at Jun. 30, 2024 $ 19,344 $ (12,151) $ 7,193
Balance (in Shares) at Jun. 30, 2024 9,177,100     9,177,100
[1] Except share and per share information